1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnosis
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company Profiles
6.1. Novartis
6.2. GlaxoSmithKline plc.
6.3. Orchard Therapeutics
6.4. Acceleron Pharma, Inc.
6.5. Celgene Corporation
6.6. Sanofi Genzyme
6.7. Sangamo Therapeutics
6.8. Bluebird bio, Inc.
6.9. La Jolla Pharmaceutical Company
6.10. Ionis Pharmaceuticals Inc.
6.11. Imara Inc.
6.12. CRISPR Therapeutics AG
6.13. Protagonist Therapeutics, Inc.
6.14. Errant Gene Therapeutics
6.15. Agios Inc.
6.16. Silence Therapeutics
6.17. CSL Behring
6.18. Editas Medicine
6.19. Vifor Pharma
6.20. Kiadis Pharma
List of Tables
List of Figures